SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors are a family of anti‐T2DM medications that function by inhibiting glucose reabsorption in renal tubules and have shown promising results in reducing CVD‐related morbidity and mortality (Buse et al. 2020).